Zai Lab Limited (ZLAB)

Market Cap	1.87B
Revenue (ttm)	291.07M
Net Income (ttm)	-338.95M
Shares Out	99.12M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	659,442
Open	19.18
Previous Close	18.87
Day's Range	18.60 - 19.61
52-Week Range	13.48 - 32.60
Beta	1.05
Analysts	Strong Buy
Price Target	56.21 (+198.04%)
Earnings Date	Aug 6, 2024

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia grav...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 2,175
• Stock Exchange: NASDAQ
• Ticker Symbol: ZLAB

Financial Performance

In 2023, Zai Lab's revenue was $266.72 million, an increase of 24.03% compared to the previous year's $215.04 million. Losses were -$334.62 million, -24.51% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price forecast is $56.21, which is an increase of 198.04% from the latest price.

Price Target

$56.21

(198.04% upside)

Analyst Consensus: Strong Buy